(Q37996076)

26 August 2017

title

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

1

Caroline M Perry

1 reference

26 August 2017

publication date

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

72

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

619-641

1 reference

https://scigraph.springernature.com/pub.10.2165/11208370-000000000-00000

26 August 2017

exact match

0 references

cites work

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Therapeutic implications of hepatitis C virus resistance to antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Treatment failure with new hepatitis C drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Drugs in development for viral hepatitis: care and caution

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208370-000000000-00000

Effect of telaprevir on the pharmacokinetics of midazolam and digoxin

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22439668

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22439668

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22439668

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2165/11208370-000000000-00000

1 reference

Dimensions Publication ID

26 August 2017

1018743594

0 references

1 reference